Delivery Order SPE2DR25D3201-SPE2DR26FT4CR
- Not listed
- The Defense Logistics Agency awarded a $11,087.60 delivery order to AmerisourceBergen Drug Corp for Padcev 30 mg vials, with an ultimate completion date of August 8, 2025. This is a firm fixed-price, non-set-aside contract with performance in Conshohocken, Pennsylvania. The delivery order was awarded on July 18, 2025, as part of AmerisourceBergen's broader engagement with the federal government for pharmaceutical supply. This delivery order falls under AmerisourceBergen's substantial...
- The Defense Logistics Agency awarded a delivery order valued at $5,543.85 to AmerisourceBergen Drug Corp for Padcev 20 mg vials on November 4, 2025, with an ultimate completion date of November 26, 2025. This firm fixed-price delivery order is non-set-aside and competitively awarded, with performance to be fulfilled at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $11,087.70 delivery order to AmerisourceBergen Drug Corp for the supply of Padcev 20 mg vials, with performance to be completed by September 23, 2025. This competitively awarded, firm fixed-price contract is being executed from the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order valued at $11,087.60 to AmerisourceBergen Drug Corp for the supply of Padcev 30 mg vials. This competitively awarded, firm fixed price contract was executed on September 2, 2025, with an ultimate completion date of September 23, 2025. The pharmaceutical distributor will perform the delivery at its corporate office location in Conshohocken, Pennsylvania. As a non-set-aside procurement, this award reflects AmerisourceBergen's continued...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $7,391.80 delivery order for Padcev 20 mg vials under a firm fixed-price contract with an ultimate completion date of August 11, 2025. This is a non-set-aside award, meaning it was competitively awarded without restrictions. The order will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical distributor serving federal medical procurement needs,...
- The Defense Logistics Agency awarded a delivery order valued at $14,783.60 to AmerisourceBergen Drug Corp for Padcev 20 mg vials, with a firm fixed price and an ultimate completion date of December 1, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 and extends through December 2026. The...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of PADCEV 30 mg vials, a specialized pharmaceutical product. This firm fixed-price delivery order carries a ceiling value of $27.7K and is scheduled for completion by August 4, 2025. The contract was awarded competitively with no set-aside designation, and performance will occur at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $8,315.70 to AmerisourceBergen Drug Corp for PADCEV 30 mg vials, a pharmaceutical product used in cancer treatment. The contract, issued on August 25, 2025, with an ultimate completion date of September 16, 2025, carries firm fixed pricing under a non-competitive, non-set-aside delivery order arrangement. Performance will occur at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,543.85 to AmerisourceBergen Drug Corp for the supply of Padcev 20 mg vials, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for PADCEV 20 mg vials, with a ceiling value of $5,543.85 and a firm fixed price arrangement. The order is scheduled for completion by August 27, 2025. This is a non-set-aside, competitively awarded contract supporting the federal government's pharmaceutical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate...
- SPE2DR25D3201Indefinite Delivery Contract
- SPE2DR25D3201-SPE2DR26FT4CRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of Padcev 20 mg vials, a chemotherapy medication used in cancer treatment. This competitively awarded, firm fixed-price delivery order has a ceiling value of $15,579.68 and is scheduled for completion by December 10, 2025. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor supporting federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to military healthcare systems and other government agencies. The firm fixed-price structure and competitive award reflect the company's established capability to meet federal pharmaceutical supply requirements across multiple therapeutic domains at favorable pricing.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.6k | 11/18/25 |